Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6753162B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 24, 1995 |
| Grant date | Jun 22, 2004 |
| Priority date | — |
| Expiry date | Feb 24, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/023
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed is a second method of treating HIV in a mammal involving administering to the mammal an effective amount of therapeutic cells expressing a membrane-bound, proteinaceous chimeric receptor comprising an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.